Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115674 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Lev Demidov und 49 weiteren Autor:innen. Beteiligte Einrichtung: FSBI "N.N. Blokhin National Medical Research Center for Oncology", MoH, Moscow, Russian Federation. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Russian Venture Company.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- FSBI "N.N. Blokhin National Medical Research Center for Oncology", MoH, Moscow, Russian Federation.
- SBHI "N.P. Napalkov St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncology)", St. Petersburg, Russian Federation.
- Hadassah Medical LCC, Moscow, Russian Federation.
- Moscow City Oncology Hospital No. 62, Moscow, Russian Federation.
- SBHI "Novosibirsk Regional Clinical Oncology Dispensary", Novosibirsk, Russian Federation.
- BHI "Clinical Oncology Dispensary", Omsk, Russian Federation.
Förderung
- Russian Venture Company
Zitieren
APA
Demidov, L., Samoylenko, I., Kharkevich, G., Orlova, K., Moiseenko, V., Utyashev, I., Stroyakovskiy, D., Kozlov, V., Zimina, A., Mochalova, A., Demidova, S., Lyadova, M., Kutkovich, A., Skopin, P., Kovalenko, N., Safina, S., Volkov, V., Semiletova, Y., Vaschenko, V., …, & Kryukov, F. (2025). Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115674
Vancouver
Demidov L, Samoylenko I, Kharkevich G, Orlova K, Moiseenko V, Utyashev I, et al. Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115674
BibTeX
@article{Demidov2025,
author = {Demidov, Lev and Samoylenko, Igor and Kharkevich, Galina and Orlova, Kristina and Moiseenko, Vladimir and Utyashev, Igor and Stroyakovskiy, Daniil and Kozlov, Vadim and Zimina, Anastasia and Mochalova, Anastasia and Demidova, Svetlana and Lyadova, Marina and Kutkovich, Andrey and Skopin, Pavel and Kovalenko, Nadezhda and Safina, Sufia and Volkov, Vitaliy and Semiletova, Yulia and Vaschenko, Vera and Kislov, Nikolay and Poltoratskiy, Artem and Shumskaya, Irina and Kolomiets, Sergey and Sobolev, Alexandr and Belogortsev, Igor and Odintsova, Svetlana and Rastogi, Sameer and Andabekov, Timur and Penkov, Konstantin and Semenova, Anna and Obukhov, Alexey and Belyakovsky, Vasiliy and Yurchenkov, Alexander and Gladkov, Oleg and Neve, Rakesh and Falaleeva, Natalia and Poddubskaya, Elena and Vaibhav, Amale and Kirtbaya, Dmitriy and Chapko, Yana and Smagina, Maria and Fadeeva, Natalya and Sorokina, Irina and Mikhailova, Evgenia and Linkova, Yulia and Zinkina-Orikhan, Arina and Lutskii, Anton and Gabidullin, Rishat and Rzaev, Roman and Kryukov, Fedor},
title = {Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115674}
}
EUVIMED